OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Related Articles
SEQUOIA Extended Follow-Up Supports Initial Findings in CLL/SLL | Blood Cancers Today
After five years of follow-up in the phase 3 SEQUOIA study, first-line zanubrutinib treatment continues to demonstrate an improvement in progression-free survival in CLL versus…
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
FY25 FDA Broad Agency Announcement – Q&A Session
FY25 FDA Broad Agency Announcement – Question and Answer Session
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma
Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.
Integrating cancer into crisis: a global vision for action from WHO and partners
More than a billion people live in fragile, conflict-affected, and vulnerable settings requiring humanitarian support, where cancer is a substantial health issue. Despite its substantial…
Blocking a cancer escape hatch
Fred Hutch graduate student Adam Nguyen has won a F31 training award from the NIH to study a complex molecule called Tie2 that aids and…
Registration
Prices are based on membership status. Once logged in, the correct registration rate will automatically populate. Physician, Scientist, Industry (Non-Exhibitor), PhD, Other $749 Resident/Student, Fellow,…
Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma
Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.